BlackRock Fund Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | $78.7M | Buy |
2,100,902
+173,565
| +9% | +$6.5M | 0.01% | 1382 |
|
|
2016
Q3 | $131M | Buy |
1,927,337
+56,455
| +3% | +$3.83M | 0.03% | 875 |
|
|
2016
Q2 | $104M | Buy |
1,870,882
+32,506
| +2% | +$1.8M | 0.02% | 946 |
|
|
2016
Q1 | $115M | Buy |
1,838,376
+112,252
| +7% | +$7.05M | 0.03% | 837 |
|
|
2015
Q4 | $162M | Sell |
1,726,124
-177,587
| -9% | -$16.7M | 0.04% | 605 |
|
|
2015
Q3 | $153M | Buy |
1,903,711
+121,946
| +7% | +$9.8M | 0.04% | 604 |
|
|
2015
Q2 | $214M | Buy |
1,781,765
+89,153
| +5% | +$10.7M | 0.05% | 429 |
|
|
2015
Q1 | $177M | Buy |
1,692,612
+237,280
| +16% | +$24.8M | 0.04% | 572 |
|
|
2014
Q4 | $141M | Sell |
1,455,332
-10,963
| -0.7% | -$1.06M | 0.03% | 674 |
|
|
2014
Q3 | $115M | Buy |
1,466,295
+58,472
| +4% | +$4.57M | 0.03% | 735 |
|
|
2014
Q2 | $88.9M | Sell |
1,407,823
-902,180
| -39% | -$57M | 0.03% | 971 |
|
|
2014
Q1 | $155M | Buy |
2,310,003
+96,481
| +4% | +$6.48M | 0.05% | 519 |
|
|
2013
Q4 | $142M | Sell |
2,213,522
-35,480
| -2% | -$2.28M | 0.04% | 571 |
|
|
2013
Q3 | $144M | Buy |
2,249,002
+337,517
| +18% | +$21.6M | 0.05% | 490 |
|
|
2013
Q2 | $59.3M | Buy |
+1,911,485
| New | +$59.3M | 0.02% | 1078 |
|